Targeted therapy in older patients with solid tumors

Journal of Clinical Oncology

Volumn 32, Issue 24, 2014, Pages 2635-2646

  Kelly, Ciara M ^a   Power, Derek G ^a   Lichtman, Stuart M ^b  

^a MERCY UNIVERSITY HOSPITAL   (Ireland)

^b MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AFLIBERCEPT; ANASTROZOLE; AXITINIB; BEVACIZUMAB; CETUXIMAB; CRIZOTINIB; EPIDERMAL GROWTH FACTOR RECEPTOR KINASE INHIBITOR; ERLOTINIB; EVEROLIMUS; GEFITINIB; IMATINIB; IPILIMUMAB; LAPATINIB; MAMMALIAN TARGET OF RAPAMYCIN INHIBITOR; PANITUMUMAB; PAZOPANIB; PERTUZUMAB; RAMUCIRUMAB; REGORAFENIB; SORAFENIB; SUNITINIB; TEMSIROLIMUS; TRASTUZUMAB; TRASTUZUMAB EMTANSINE; B RAF KINASE; BRAF PROTEIN, HUMAN; MTOR PROTEIN, HUMAN; PROTEIN KINASE INHIBITOR; TARGET OF RAPAMYCIN KINASE;

AGED; BREAST CANCER; CANCER CHEMOTHERAPY; CANCER PATIENT; COLORECTAL CANCER; GASTROINTESTINAL STROMAL TUMOR; HUMAN; KIDNEY CARCINOMA; LIVER CELL CARCINOMA; LUNG NON SMALL CELL CANCER; MELANOMA; PATIENT SELECTION; PRIORITY JOURNAL; REVIEW; SOLID TUMOR; STOMACH CANCER; AGE; ANTAGONISTS AND INHIBITORS; ENZYMOLOGY; GENETICS; MOLECULARLY TARGETED THERAPY; NEOPLASMS; PERSONALIZED MEDICINE; VERY ELDERLY;

AGE FACTORS; AGED; AGED, 80 AND OVER; HUMANS; INDIVIDUALIZED MEDICINE; MOLECULAR TARGETED THERAPY; NEOPLASMS; PROTEIN KINASE INHIBITORS; PROTO-ONCOGENE PROTEINS B-RAF; TOR SERINE-THREONINE KINASES;

EID: 84906234225     PISSN: 0732183X     EISSN: 15277755     Source Type: Journal    
DOI: 10.1200/JCO.2014.55.4246     Document Type: Review

References (95)

1. La Thangue NB, Kerr DJ: Predictive biomarkers: A paradigm shift towards personalized cancer medicine. Nat Rev Clin Oncol 8:587-596, 2011
2. Schilsky RL: Personalized medicine in oncology: The future is now. Nat Rev Drug Discov 9:363-366, 2010
3. Duffy MJ, Crown J: A personalized approach to cancer treatment: How biomarkers can help. Clin Chem 54:1770-1779, 2008
4. Scher KS, Hurria A: Under-representation of older adults in cancer registration trials: Known problem, little progress. J Clin Oncol 30:2036-2038, 2012
5. Dematteo RP, Ballman KV, Antonescu CR, et al: Adjuvant imatinib mesylate after resection of localised, primary gastrointestinal stromal tumour: A randomised, double-blind, placebo-controlled trial. Lancet 373:1097-1104, 2009
6. Casali PG, Le Cesne A, Velasco AP, et al: Imatinib failure-free survival (IFS) in patients with localized gastrointestinal stromal tumors (GIST) treated with adjuvant imatinib (IM): The EORTC/AGITG/FSG/GEIS/ISG randomized controlled phase III trial. J Clin Oncol 31, 2013 (suppl 15s; abstr 10500)
7. Joensuu H, Eriksson M, Sundby Hall K, et al: One vs three years of adjuvant imatinib for operable gastrointestinal stromal tumor: A randomized trial. JAMA 307:1265-1272, 2012
8. Mok TS, Wu YL, Thongprasert S, et al: Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma. N Engl J Med 361:947-957, 2009
9. Crinò L, Cappuzzo F, Zatloukal P, et al: Gefitinib versus vinorelbine in chemotherapy-naive elderly patients with advanced non-small-cell lung cancer (INVITE): A randomized, phase II study. J Clin Oncol 26:4253-4260, 2008
10. Shepherd FA, Rodrigues Pereira J, Ciuleanu T, et al: Erlotinib in previously treated non-small-cell lung cancer. N Engl J Med 353:123-132, 2005 (Pubitemid 41058344)
11. Rosell R, Carcereny E, Gervais R, et al: Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): A multicentre, open-label, randomised phase 3 trial. Lancet Oncol 13:239-246, 2012
12. Llovet JM, Ricci S, Mazzaferro V, et al: Sorafenib in advanced hepatocellular carcinoma. N Engl J Med 359:378-390, 2008
13. Baselga J, Campone M, Piccart M, et al: Everolimus in postmenopausal hormone-receptorpositive advanced breast cancer. N Engl J Med 366:520-529, 2012
14. Piccart-Gebhart MJ, Procter M, Leyland-Jones B, et al: Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer. N Engl J Med 353:1659-1672, 2005 (Pubitemid 41464705)
15. Baselga J, Cortés J, Kim SB, et al: Pertuzumab plus trastuzumab plus docetaxel for metastatic breast cancer. N Engl J Med 366:109-119, 2012
16. Verma S, Miles D, Gianni L, et al: Trastuzumab emtansine for HER2-positive advanced breast cancer. N Engl J Med 367:1783-1791, 2012
17. Chapman PB, Hauschild A, Robert C, et al: Improved survival with vemurafenib in melanoma with BRAF V600E mutation. N Engl J Med 364: 2507-2516, 2011
18. Hauschild A, Grob JJ, Demidov LV, et al: Dabrafenib in BRAF-mutated metastatic melanoma: A multicentre, open-label, phase 3 randomised controlled trial. Lancet 380:358-365, 2012
19. Hodi FS, O'Day SJ, McDermott DF, et al: Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med 363:711-723, 2010
20. Motzer RJ, Hutson TE, Tomczak P, et al: Sunitinib versus interferon alfa in metastatic renalcell carcinoma. N Engl J Med 356:115-124, 2007 (Pubitemid 46089672)
21. Sternberg CN, Davis ID, Mardiak J, et al: Pazopanib in locally advanced or metastatic renal cell carcinoma: Results of a randomized phase III trial. J Clin Oncol 28:1061-1068, 2010
22. Escudier B, Eisen T, Stadler WM, et al: Sorafenib in advanced clear-cell renal-cell carcinoma. N Engl J Med 356:125-134, 2007 (Pubitemid 46089673)
23. Rini BI, Escudier B, Tomczak P, et al: Comparative effectiveness of axitinib versus sorafenib in advanced renal cell carcinoma (AXIS): A randomised phase 3 trial. Lancet 378:1931-1939, 2011
24. Van Cutsem E, Köhne CH, Hitre E, et al: Cetuximab and chemotherapy as initial treatment for metastatic colorectal cancer. N Engl J Med 360:1408-1417, 2009
25. Douillard JY, Siena S, Cassidy J, et al: Randomized, phase III trial of panitumumab with infusional fluorouracil, leucovorin, and oxaliplatin (FOLFOX4) versus FOLFOX4 alone as first-line treatment in patients with previously untreated metastatic colorectal cancer: The PRIME study. J Clin Oncol 28:4697-4705, 2010
26. Bang YJ, Van Cutsem E, Feyereislova A, et al: Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): A phase 3, open-label, randomised controlled trial. Lancet 376:687-697, 2010
27. Hirota S, Isozaki K, Moriyama Y, et al: Gain-offunction mutations of c-kit in human gastrointestinal stromal tumors. Science 279:577-580, 1998 (Pubitemid 28067289)
28. Heinrich MC, Corless CL, Duensing A, et al: PDGFRA activating mutations in gastrointestinal stromal tumors. Science 299:708-710, 2003 (Pubitemid 36159485)
29. Hayat MJ, Howlader N, Reichman ME, et al: Cancer statistics, trends, and multiple primary cancer analyses from the Surveillance, Epidemiology, and End Results (SEER) Program. Oncologist 12:20-37, 2007 (Pubitemid 46143500)
30. Keedy VL, Temin S, Somerfield MR, et al: American Society of Clinical Oncology provisional clinical opinion: Epidermal growth factor receptor (EGFR) mutation testing for patients with advanced non-small-cell lung cancer considering first-line EGFR tyrosine kinase inhibitor therapy. J Clin Oncol 29:2121-2127, 2011
31. Peters S, Adjei AA, Gridelli C, et al: Metastatic non-small-cell lung cancer (NSCLC): ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 23:vii56-vii64, 2012
32. Riely GJ, Chaft JE, Ladanyi M, et al: Incorporation of crizotinib into the NCCN guidelines. J Natl Compr Canc Netw 9:1328-1330, 2011
33. Wheatley-Price P, Ding K, Seymour L, et al: Erlotinib for advanced non-small-cell lung cancer in the elderly: An analysis of the National Cancer Institute of Canada Clinical Trials Group Study BR.21. J Clin Oncol 26:2350-2357, 2008
34. Jackman DM, Yeap BY, Lindeman NI, et al: Phase II clinical trial of chemotherapy-naive patients > or = 70 years of age treated with erlotinib for advanced non-small-cell lung cancer. J Clin Oncol 25:760-766, 2007 (Pubitemid 350002874)
35. Camidge DR, Bang YJ, Kwak EL, et al: Activity and safety of crizotinib in patients with ALK-positive non-small-cell lung cancer: Updated results from a phase 1 study. Lancet Oncol 13:1011-1019, 2012
36. Shaw AT, Kim DW, Nakagawa K, et al: Crizotinib versus chemotherapy in advanced ALK-positive lung cancer. N Engl J Med 368:2385-2394, 2013
37. Montella L, Addeo R, Cennamo G, et al: Sorafenib in elderly patients with advanced hepatocellular carcinoma: A case series. Oncology 84:265-272, 2013
38. Incorvati JA, Shah S, Mu Y, et al: Targeted therapy for HER2 positive breast cancer. J Hematol Oncol 6:38, 2013
39. Slamon DJ, Leyland-Jones B, Shak S, et al: Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med 344:783-792, 2001 (Pubitemid 32222155)
40. Chavez-MacGregor M, Zhang N, Buchholz TA, et al: Trastuzumab-related cardiotoxicity among older patients with breast cancer. J Clin Oncol 31:4222-4228, 2013
41. Cardinale D, Colombo A, Torrisi R, et al: Trastuzumab-induced cardiotoxicity: Clinical and prognostic implications of troponin I evaluation. J Clin Oncol 28:3910-3916, 2010
42. Slamon D, Eiermann W, Robert N, et al: Adjuvant trastuzumab in HER2-positive breast cancer. N Engl J Med 365:1273-1283, 2011
43. Romond EH, Perez EA, Bryant J, et al: Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer. N Engl J Med 353: 1673-1684, 2005 (Pubitemid 41464706)
44. Serrano C, Cortés J, De Mattos-Arruda L, et al: Trastuzumab-related cardiotoxicity in the elderly: A role for cardiovascular risk factors. Ann Oncol 23:897-902, 2012
45. Sawaki M, Mukai H, Tokudome N, et al: Safety of adjuvant trastuzumab for HER-2-overexpressing elderly breast cancer patients: A multicenter cohort study. Breast Cancer 19:253-258, 2012
46. Zucchini G, Bernardi A, Martoni A, et al: Tolerability and activity of trastuzumab in elderly patients with HER2-overexpressing metastatic breast cancer. Ann Oncol 24:264-265, 2013
47. Adamo V, Ricciardi GR, Adamo B, et al: The risk of toxicities from trastuzumab, alone or in combination, in an elderly breast cancer population. Oncology 86:16-21, 2014
48. Tsai HT, Isaacs C, Fu AZ, et al: Risk of cardiovascular adverse events from trastuzumab (Herceptin(®) in elderly persons with breast cancer: A population-based study. Breast Cancer Res Treat 144:163-170, 2014
49. Brunello A, Monfardini S, Crivellari D, et al: Multicenter analysis of activity and safety of trastuzumab plus chemotherapy in advanced breast cancer in elderly women (≥ 70 years). J Clin Oncol 26:65s, 2008 (suppl; abstr 1096)
50. Dodwell D, Wardley A, Johnston S: Postmenopausal advanced breast cancer: Options for therapy after tamoxifen and aromatase inhibitors. Breast 15:584-594, 2006 (Pubitemid 44509773)
51. Pritchard KI, Burris HA 3rd, Ito Y, et al: Safety and efficacy of everolimus with exemestane vs. exemestane alone in elderly patients with HER2-negative, hormone receptor-positive breast cancer in BOLERO-2. Clin Breast Cancer 13:421.e8-432.e8, 2013
52. Biganzoli L, Wildiers H, Oakman C, et al: Management of elderly patients with breast cancer: Updated recommendations of the International Society of Geriatric Oncology (SIOG) and European Society of Breast Cancer Specialists (EUSOMA). Lancet Oncol 13:e148-e160, 2012
53. Johnston S, Pippen J Jr, Pivot X, et al: Lapatinib combined with letrozole versus letrozole and placebo as first-line therapy for postmenopausal hormone receptor-positive metastatic breast cancer. J Clin Oncol 27:5538-5546, 2009
54. Kaufman B, Mackey JR, Clemens MR, et al: Trastuzumab plus anastrozole versus anastrozole alone for the treatment of postmenopausal women with human epidermal growth factor receptor 2-positive, hormone receptor-positive metastatic breast cancer: Results from the randomized phase III TAnDEM study. J Clin Oncol 27:5529-5537, 2009
55. Geyer CE, Forster J, Lindquist D, et al: Lapatinib plus capecitabine for HER2-positive advanced breast cancer. N Engl J Med 355:2733-2743, 2006 (Pubitemid 46021510)
56. GlaxoSmithKline: Highlights of prescribing information (lapatinib product insert). http://us.gsk.com/products/assets/us-tykerb.pdf
57. Crown JP, Burris HA 3rd, Boyle F, et al: Pooled analysis of diarrhea events in patients with cancer treated with lapatinib. Breast Cancer Res Treat 112:317-325, 2008
58. Curtin JA, Fridlyand J, Kageshita T, et al: Distinct sets of genetic alterations in melanoma. N Engl J Med 353:2135-2147, 2005 (Pubitemid 41653105)
59. Maker AV, Attia P, Rosenberg SA: Analysis of the cellular mechanism of antitumor responses and autoimmunity in patients treated with CTLA-4 blockade. J Immunol 175:7746-7754, 2005 (Pubitemid 41713475)
60. Quivy A, Daste A, Harbaoui A, et al: Optimal management of renal cell carcinoma in the elderly: A review. Clin Interv Aging 8:433-442, 2013
61. Huston TE, Bukowski RM, Rini BI, et al: A pooled analysis of the efficacy and safety of sunitinib in elderly patients (pts) with metastatic renal cell carcinoma (mRCC). J Clin Oncol 29:314s, 2011 (suppl; abstr 4604)
62. De Giorgi U, Rihawi K, Lo Re G, et al: Sunitinib as first-line therapy in elderly patients (age 70 and older) with metastatic renal cell cancer. J Clin Oncol 30, 2012 (suppl; abstr 411)
63. Motzer RJ, Hutson TE, Cella D, et al: Pazopanib versus sunitinib in metastatic renal-cell carcinoma. N Engl J Med 369:722-731, 2013
64. Eisen T, Oudard S, Szczylik C, et al: Clinical benefit of sorafenib in the elderly with advanced renal cell carcinoma: Subgroup analysis of the Approaches in Renal Cell Cancer Global Evaluation Trial (TARGETS). Ann Oncol 17, 2006 (suppl 9; abstr 446PD)
65. Procopio G, Bellmunt J, Dutcher J, et al: Sorafenib tolerability in elderly patients with advanced renal cell carcinoma: Results from a large pooled analysis. Br J Cancer 108:311-318, 2013
66. Motzer RJ, Escudier B, Oudard S, et al: Efficacy of everolimus in advanced renal cell carcinoma: A doubleblind, randomised, placebo-controlled phase III trial. Lancet 372:449-456, 2008
67. Porta C, Calvo E, Climent MA, et al: Efficacy and safety of everolimus in elderly patients with metastatic renal cell carcinoma: An exploratory analysis of the outcomes of elderly patients in the RECORD-1 Trial. Eur Urol 61:826-833, 2012
68. Hudes G, Carducci M, Tomczak P, et al: Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma. N Engl J Med 356:2271-2281, 2007 (Pubitemid 46849157)
69. Dutcher JP, Szczylik C, Tannir N, et al: Correlation of survival with tumor histology, age, and prognostic risk group for previously untreated patients with advanced renal cell carcinoma (adv RCC) receiving temsirolimus (TEMSR) or interferon-alpha (IFN). J Clin Oncol 25:243s, 2007 (suppl; abstr 5033)
70. Motzer RJ, Escudier B, Tomczak P, et al: Axitinib versus sorafenib as second-line treatment for advanced renal cell carcinoma: Overall survival analysis and updated results from a randomised phase 3 trial. Lancet Oncol 14:552-562, 2013
71. Douillard JY, Oliner KS, Siena S, et al: Panitumumab-FOLFOX4 treatment and RAS mutations in colorectal cancer. N Engl J Med 369:1023-1034, 2013
72. Jehn CF, Böning L, Kröning H, et al: Influence of comorbidity, age and performance status on treatment efficacy and safety of cetuximab plus irinotecan in irinotecan-refractory elderly patients with metastatic colorectal cancer. Eur J Cancer 50:1269-1275, 2014
73. Amado RG, Wolf M, Peeters M, et al: Wildtype KRAS is required for panitumumab efficacy in patients with metastatic colorectal cancer. J Clin Oncol 26:1626-1634, 2008
74. Peeters M, Price TJ, Cervantes A, et al: Randomized phase III study of panitumumab with fluorouracil, leucovorin, and irinotecan (FOLFIRI) compared with FOLFIRI alone as second-line treatment in patients with metastatic colorectal cancer. J Clin Oncol 28:4706-4713, 2010
75. Köhne CH, Folprecht G, Goldberg RM, et al: Chemotherapy in elderly patients with colorectal cancer. Oncologist 13:390-402, 2008 (Pubitemid 351679918)
76. ClinicalTrials.gov: Bevacizumab Plus Capecitabine (Xeloda) in Patients With Untreated Metastatic Colorectal Cancer. http://clinicaltrials.gov/show/ NCT00203411
77. Cunningham D, Lang I, Marcuello E, et al: Bevacizumab plus capecitabine versus capecitabine alone in elderly patients with previously untreated metastatic colorectal cancer (AVEX): An open-label, randomised phase 3 trial. Lancet Oncol 14:1077-1085, 2013
78. Geiger-Gritsch S, Stollenwerk B, Miksad R, et al: Safety of bevacizumab in patients with advanced cancer: A meta-analysis of randomized controlled trials. Oncologist 15:1179-1191, 2010
79. Raman AK, Lombardo JC, Chandrasekhar R, et al: Bevacizumab (BV) related adverse events among various age groups of elderly patients with advanced colorectal cancer. J Clin Oncol 25:628s, 2007 (suppl; abstr 14546)
80. Kozloff MF, Berlin J, Flynn PJ, et al: Clinical outcomes in elderly patients with metastatic colorectal cancer receiving bevacizumab and chemotherapy: Results from the BRiTE observational cohort study. Oncology 78:329-339, 2010
81. Escalante CP, Zalpour A: Vascular endothelial growth factor inhibitor-induced hypertension: Basics for primary care providers. Cardiol Res Pract 2011: 816897, 2011
82. Cohen AT, Gurwith MM, Dobromirski M: Thromboprophylaxis in non-surgical cancer patients. Thromb Res 129:S137-S145, 2012
83. Nalluri SR, Chu D, Keresztes R, et al: Risk of venous thromboembolism with the angiogenesis inhibitor bevacizumab in cancer patients: A metaanalysis. JAMA 300:2277-2285, 2008
84. Hurwitz HI, Saltz LB, Van Cutsem E, et al: Venous thromboembolic events with chemotherapy plus bevacizumab: A pooled analysis of patients in randomized phase II and III studies. J Clin Oncol 29:1757-1764, 2011
85. Aprile G, Fontanella C, Lutrino ES, et al: Angiogenic inhibitors for older patients with advanced colorectal cancer: Does the age hold the stage? World J Gastroenterol 19:2131-2140, 2013
86. Tebbutt NC, Murphy F, Zannino D, et al: Risk of arterial thromboembolic events in patients with advanced colorectal cancer receiving bevacizumab. Ann Oncol 22:1834-1838, 2011
87. Van Cutsem E, Tabernero J, Lakomy R, et al: Addition of aflibercept to fluorouracil, leucovorin, and irinotecan improves survival in a phase III randomized trial in patients with metastatic colorectal cancer previously treated with an oxaliplatin-based regimen. J Clin Oncol 30:3499-3506, 2012
88. Grothey A, Van Cutsem E, Sobrero A, et al: Regorafenib monotherapy for previously treated metastatic colorectal cancer (CORRECT): An international, multicentre, randomised, placebo-controlled, phase 3 trial. Lancet 381:303-312, 2013
89. Fuchs CS, Tomasek J, Yong CJ, et al: Ramucirumab monotherapy for previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (REGARD): An international, randomised, multicentre, placebo-controlled, phase 3 trial. Lancet 383:31-39, 2014
90. Eli Lilly: Highlights of prescribing information for CYRAMZA, a human vascular endothelial growth factor receptor 2 (VEGFR2) antagonist. http://www.accessdata.fda.gov/drugsatfda-docs/label/2014/125477lbl.pdf
91. Extermann M, Boler I, Reich RR, et al: Predicting the risk of chemotherapy toxicity in older patients: The Chemotherapy Risk Assessment Scale for High-Age Patients (CRASH) score. Cancer 118:3377-3386, 2012
92. Hurria A, Togawa K, Mohile SG, et al: Predicting chemotherapy toxicity in older adults with cancer: A prospective multicenter study. J Clin Oncol 29:3457-3465, 2011
93. Lichtman SM: Call for changes in clinical trial reporting of older patients with cancer. J Clin Oncol 30:893-894, 2012
94. Lichtman SM: Clinical trial design in older adults with cancer: The need for new paradigms. J Geriatr Oncol 3:368-375, 2012
95. Wildiers H, Mauer M, Pallis A, et al: End points and trial design in geriatric oncology research: A joint European Organisation for Research and Treatment of Cancer-Alliance for Clinical Trials in Oncology-International Society of Geriatric Oncology position article. J Clin Oncol 31:3711-3718, 2013